Familial Hypercholesterolemia

Cardiovascular Risk Reduction With PCSK9 Inhibitors: Evolving Evidence, Recommendations, and Controversies

Cardiovascular Risk Reduction With PCSK9 Inhibitors: Evolving Evidence, Recommendations, and Controversies

Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors have prov…

Expiration Date: 7/15/2020

Max Credits: 0.75

View Activity

Back to the Future: Clinical Experience with and Access to Lipid-Lowering Agents of the Past, Present, and Future

Back to the Future: Clinical Experience with and Access to Lipid-Lowering Agents of the Past, Present, and Future

With each passing year we gain new insight and understanding around the cl…

Expiration Date: 8/11/2018

Max Credits: 0

View Activity